♟ Profit Off the FDA's Next Major Decision

Here's how you can get in on a free upside pick! [Trade of the Day Logo] [View in browser]( [Image of the Vertex]( ["If you make this trade, then the day this news breaks - no matter whether it's good or bad - you'll be properly positioned to cash in."]( Bryan Bottarelli, Head Trade Tactician, Monument Traders Alliance [Robert Ross] Today I'm going to give you an inside look into what it's like to be part of our elite trading group... And of course, it all centers around an enormous winning trade. Here's the scoop... Whenever I see fellow War Room members at financial shows or investment conferences, the winner that most often comes up in conversation is Biogen (BIIB). In case you aren't familiar with this trade, Biogen was waiting for a major FDA decision on a landmark Alzheimer's drug candidate, and I recommended playing a two-sided call/put strangle to be ready for either an approval or a rejection. Either one would've had tremendous consequences for the stock, which is why we got positioned to profit off an explosive move to the upside OR the downside. As it turned out, Biogen ripped higher, which resulted in a huge winner for us. (It later ended up falling back down... but by then, it didn't matter!) The stock ended up being a roller coaster for most investors. But traders like us cleaned house off the intense volatility the day the news broke. The reason I bring this up to you now is I think we could be facing a very similar situation with Vertex Pharmaceuticals (VRTX). [Wall Street's Best-Kept Income Secret]( Discover the alternative income secret boasting gains of up to 1,984% in just three years. [CLICK HERE TO LEARN MORE.]( Here's the rundown... Just as BIIB had a groundbreaking drug candidate to treat Alzheimer's, VRTX is currently developing what could be a groundbreaking drug in the area of pain relief. The name of this drug candidate, VX-548, sounds like a droid from Star Wars - but that's just how the FDA names these studies. All we need to know is this drug candidate could be a nonaddictive pain pill that eliminates the use of opioids. No matter whether it's prescribed after a tummy tuck or bunion surgery (which I hear can be quite painful), this new pain relief drug could truly be transformative for the entire medical industry. And it could be far more effective than the current treatment, which is essentially ibuprofen. The results of three VRTX studies are expected to be announced either late this year or early next year, and the market reaction could be substantial. According to Leerink Partners, sales of VX-548 could be over $5 billion if the study yields successful results. And according to Goldman Sachs analyst Salveen Richter, that could equate to a stock move of between $60 and $120, depending on the strength of the results. [Vertex Offers Strong Upside Potential]( [Logo] YOUR ACTION PLAN In this Wednesday's issue of Trade of the Day Plus, I'll be revealing the exact trade to get into right now to benefit regardless of whether VRTX soars or crashes based on the upcoming FDA decision. If you have any interest in receiving this trade, then you must sign up for [Trade of the Day Plus]( right now. Join today, and you'll get this new trade alert on Wednesday, November 8, after the market closes. It'll be delivered straight to your email inbox in a unique and engaging video format. [Yes! I Want to Join Trade of the Day Plus and Receive This New Pick This Wednesday]( P.S. If you make this trade, then the day this news breaks - no matter whether it's good or bad - you'll be properly positioned to cash in. [Join today, and the pick will hit your inbox this Wednesday!]( [I Call Them "100-Percenters"]( [Marc guarantee]( "100-percenters" are dividend stocks that raise their dividends so high and so fast that they can ultimately deliver annual payouts as big as - or bigger than - the amount of cash you started with. In other words, if you had put in $1,000... you could've collected $1,000 in dividends per year. If you had put in $10,000... you would've collected $10,000 per year! [Click Here to See How It Works]( [Chart] MONDAY MARKET MINUTE - About Last Week... Wow! The market's 5% jump last week, a response to the Fed's era of interest rate hikes potentially being over, was borderline euphoric. How can we build on the best week since October 2022? That's what we'll be tracking this week. - DraftKings Seeing More Upgrades. Almost every analyst following the company has either upgraded their target price or upgraded their rating of the shares. This includes MoffettNathanson analysts (led by Robert Fishman), who raised their call on DKNG stock from "Neutral" to "Buy." - Biotech Group Gets a Nod From Major Bank. Goldman Sachs initiated Legend Biotech (LEGN) as a "Buy," calling the biotech company "best in class" thanks to its multiple myeloma drug, Carvykti. - Some More Biotech Names Garnering Interest. According to InvestingChannel, some names seeing substantial increases in search activity include Altamira Therapeutics (CYTO), which has seen a 1,073% surge in interest, and InflaRX (IFRX), which has seen a 590% surge in interest. INSIGHTS YOU MAY HAVE MISSED [Image of a man about to topple over lettered blocks spelling the word Risk]( [Is Your Portfolio Positioned for Profits?]( [Estée Lauder]( [The Anatomy of an Overnight Super-Speculation]( [Estee Lauder]( [This Pick Is Building a Backlog]( [2 Tech Setups + Santa Claus Rally Thoughts]( [Why I'm Bearish on Big Tech]( [Instagram]( [Follow Us on Instagram!]( [FACEBOOK]( [X/TWITTER]( [Trade of the Day App Banner]( [Monument Traders Alliance] Monument Traders Alliance, LLC You are receiving this email because you subscribed to Trade of the Day. To unsubscribe from Trade of the Day, [click here](. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. Forgot your password? [Click here to reset it.]( To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.507.1399 | International: +1.443.353.4977 [Website]( | [Privacy Policy]( Keep the emails you value from falling into your spam folder. [Whitelist Trade of the Day](. © 2023 Monument Traders Alliance, LLC | All Rights Reserved --------------------------------------------------------------- Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.